SHUBINVESTS I SEBI RA

@shubham_5752

Thane

3+ Years of experience

SEBI Registration INH000016913

📊 MBA | Ex-Equity Advisor | Full-Time SEBI Registered Research Analyst Founder, ShubInvest | Started my journey on the ground floor of the stock market first as an equity advisor, now as a full-time research analyst and PhD researcher. Along the way, I witnessed the everyday challenges faced by retail investors: info ... Read more

Trade Ideas

954

Opinions

948

Followers

124k

Expertise

Quantitative

Growth

Technical

Index Strategies

Market Commentary

Futures & Options

Technical Analysis

Trade Facts

Total Trades

Missed Trades

Profit Trades

Accuracy

Ask me Anything

Got a question? Ask me and I will answer it. Stay curious, stay hungry!

Posts

shared an insight ⚡️ 11 hours ago

SBI’s AI Lending Push & Yulu’s $93 Million Bet: Two Stories, One Big Shift

Imagine a small business owner walking into a bank for a loan. Earlier, the process could mean paperwork, branch visits and weeks of waiting. Now, banks are increasingly using GST records, bank statements, ITR data, credit history and other digital footprints to make lending decisions faster. SBI is pushing deeper into this model. Its automated credit-risk systems already use financial and transactional data to assess MSME borrowers, showing how AI and data could change the way India lends to small businesses. At the same time, another transformation is happening on Indian roads. Electric mobility startup Yulu has raised $93 million through equity and debt. Its plan is ambitious: expand its EV fleet from around 50,000 to 200,000 vehicles within two years and enter more cities. The company is targeting quick commerce, food delivery and other last-mile logistics opportunities. What connects these two stories? Technology is reducing friction. In banking, AI can reduce the time required to evaluate borrowers. In mobility, shared EVs and battery swapping can reduce the cost and downtime involved in running delivery vehicles. Bajaj Auto — an existing investor in Yulu and a major player in India’s two- and three-wheeler ecosystem. Mahindra & Mahindra — exposure to electric last-mile mobility, particularly electric three-wheelers. Reliance Industries — its new-energy business is preparing battery-swapping solutions for electric two-wheelers targeting logistics and delivery applications. Shriram Finance

SHRIRAMFIN

— MSME and vehicle financing exposure, including financing directed toward EV buyers. The bigger lesson is not to buy stocks simply because a theme is growing. Watch who actually converts the theme into revenue, market share and sustainable profits. AI lending and electric mobility show how technology can reduce costs, improve efficiency and create new opportunities across Indian businesses.

171

shared an insight ⚡️ 15 hours ago

India’s Drug Law Is Changing: Who Could Benefit?

Imagine a drug factory operating for more than a decade, while the central regulator doesn’t even have it properly recorded in its database. That is the bigger problem with India’s old drug-regulation system: fragmentation, weak information flow and too few inspectors. The 2025 Coldrif tragedy showed how complicated this can become. Children died in Madhya Pradesh, but the manufacturing unit was in Tamil Nadu. One regulator dealt with the consequences; another controlled the factory. The proposed 2026 reform aims to change this by moving towards more centralised licensing, stronger information-sharing and updated rules for online pharmacies, clinical trials and medical devices. But reform also creates a new question: which companies are better positioned if compliance standards become tougher and more uniform? For investors studying the theme, some Nifty 500 pharmaceutical names worth researching include: Sun Pharmaceutical Industries | Dr. Reddy’s Laboratories | Cipla | Lupin | Zydus Lifesciences

ZYDUSLIFE

| Torrent Pharmaceuticals | Divi’s Laboratories | Aurobindo Pharma Why could established players benefit? Larger pharmaceutical companies generally have greater manufacturing scale, quality-control infrastructure and regulatory capabilities. But this does not mean the proposed law will automatically increase their profits. There is another side: higher compliance costs, stricter inspections and changes in licensing could pressure companies with weaker systems. The real investment lesson is simple: When regulation becomes stricter, compliance itself can become a competitive advantage. Stronger drug regulation may reward companies with scale, quality systems, compliance capabilities and established manufacturing processes over weaker competitors.

231

shared an insight ⚡️ 18 hours ago

India’s 86-Year-Old Drug Law Is Finally Being Rewritten

Imagine buying a medicine for a child and assuming one thing: the system has already checked it. Recent cough-syrup tragedies showed why that assumption cannot always be taken for granted. India’s 1940 Drugs and Cosmetics Act is now 86 years old, while the pharmaceutical industry has become far more complex. The proposed Draft Drugs, Medical Devices & Cosmetics Bill, 2026 attempts to modernise this framework. The core problem is fragmented regulation. Drug approvals sit largely with the Centre, while manufacturing licences are handled by state regulators. This creates gaps in coordination and enforcement. India has already conducted hundreds of risk-based inspections, with regulatory action against a large number of high-risk facilities. The proposed framework could bring: • Greater centralisation of manufacturing licensing • Stronger quality-control mechanisms • Clearer rules for e-pharmacies • A modern framework for medical devices • More proportionate treatment of minor procedural violations But there is a catch. States are reluctant to surrender regulatory powers, while medical-device companies argue that devices require a separate regulatory framework because engineering products cannot simply be regulated like medicines. Stocks to watch If implementation improves quality standards and favours manufacturers with strong compliance infrastructure, established Nifty 500 healthcare names could potentially be better positioned. Sun Pharma

SUNPHARMA

| Cipla | Dr. Reddy’s Laboratories | Lupin | Divi’s Laboratories | Torrent Pharma | Zydus Lifesciences | Aurobindo Pharma | Alkem Laboratories | Poly Medicure These are stocks to study, not buy recommendations. Nifty 500 includes major healthcare companies, while Poly Medicure provides exposure to the medical-device side of the story. Regulatory reform can reshape competitive advantages, but investors should evaluate compliance strength, valuations, earnings quality and execution before investing.

282

What are the top stock recommendations by SHUBINVESTS I SEBI RA?

SHUBINVESTS I SEBI RA regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include SHRIRAMFIN, ZYDUSLIFE and SUNPHARMA. Explore SHUBINVESTS I SEBI RA's complete list of posts and trade views on their StockGro profile.

How can I follow SHUBINVESTS I SEBI RA's latest investment insights?

You can follow SHUBINVESTS I SEBI RA's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.

What is SHUBINVESTS I SEBI RA's investment strategy?

SHUBINVESTS I SEBI RA follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.

How long has SHUBINVESTS I SEBI RA been a SEBI-registered Research Analyst (RA)?

SHUBINVESTS I SEBI RA has been a SEBI-registered Research Analyst and have 3+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.

Where can I see SHUBINVESTS I SEBI RA's past performance and stock picks?

You can check SHUBINVESTS I SEBI RA's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.

How can I contact SHUBINVESTS I SEBI RA for stock market advice?

For stock market guidance from SHUBINVESTS I SEBI RA, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.

What is SHUBINVESTS I SEBI RA's track record in predicting market movements?

SHUBINVESTS I SEBI RA has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.

What is the SEBI Registration number for SHUBINVESTS I SEBI RA?

SHUBINVESTS I SEBI RA is a SEBI-registered Research Analyst with the SEBI Registration INH000016913. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.

Be Financially Free with StockGro